FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:1546 June 6, 1996 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Køber, L. PubMed Citation

To the Editor: The Trandolapril Cardiac Evaluation (TRACE) study (Dec. 21 issue),¹ a multicenter study of patients with left ventricular systolic dysfunction after myocardial infarction, showed a clear benefit of long-term treatment with trandolapril, an angiotensin-converting–enzyme (ACE) inhibitor. In selected patients (wall-motion index, <1.2; ejection fraction, <35 percent), overall mortality was reduced by 22 percent and mortality from cardiovascular causes by 25 percent.

Often underused,² beta-blockers have a benefit similar to that of trandolapril, with similar reductions in mortality in patients with myocardial infarction,³ and they are of even more benefit in the subgroups with left ventricular dysfunction.^4,5 Thus, neurohumoral . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Frances, C. D., Noguchi, H., Massie, B. M., Browner, W. S., McClellan, M. (2000). Are We Inhibited?: Renal Insufficiency Should Not Preclude the Use of ACE Inhibitors for Patients With Myocardial Infarction and Depressed Left Ventricular Function. Arch Intern Med 160: 2645-2650 [Abstract] [Full Text]